Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Reproductive Medicine, and Cachexia Development.
"Comprehensive reagent toolkit for INHA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | INHA ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View INHA Products |
| Gene Delivery | INHA Promise-ORF / Lentivirus Full-length ORF for stable cell lines and receptor-binding assays. |
View INHA Products |
| Benchmark Ab | Anti-INHA Recombinant Antibody Recombinant positive control matching clinical/diagnostic benchmark sequences. |
View INHA Products |
| Validator | INHA siRNA Set For knockdown verification in functional assays. |
View INHA Products |
| Related Target A | ACVR2B (ActRIIB) Key receptor in the Activin/Inhibin signaling pathway, crucial for cachexia drug screening. |
View ACVR2B Products |
| Related Target B | INHBA (Inhibin beta A) Dimerization partner forming Inhibin A and Activin A; essential for selectivity assays. |
View INHBA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dimerization & Glycosylation Integrity | HEK293 mammalian expression system ensures native post-translational modifications and correct folding of the alpha-subunit. |
| Subfamily Cross-reactivity & Selectivity Screening | Homolog and subunit panels (INHBA, INHBB) strictly verified by mass spectrometry to evaluate off-target binding. |
| Lack of Validated Reference Controls | Sequence-verified clinical-grade benchmark antibodies included to establish reliable assay baselines. |
| False Positives in Phenotypic Screening | Pre-validated target-specific siRNA sets provided to confirm target-dependent biological responses. |
Live Inhibin alpha/INHA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic and diagnostic targeting of Inhibin alpha (INHA) is expanding rapidly. Historically utilized as a gold-standard diagnostic biomarker for ovarian granulosa cell tumors and mucinous epithelial ovarian cancers, INHA is now gaining traction as a therapeutic node. The therapeutic focus is shifting toward modulating the broader Activin-Inhibin-TGF-beta signaling axis to address cancer-associated cachexia, muscle wasting, and reproductive endocrine disorders.
As next-generation biologics enter development, the R&D landscape is demanding highly specific monoclonal antibodies capable of differentiating between monomeric INHA, dimeric Inhibin A/B, and structurally related Activin complexes. Achieving this level of selectivity requires conformationally intact, mammalian-expressed antigens that mimic native human physiology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic mAbs | Roche, Abbott, Danaher | Ovarian Granulosa Cell Tumors, Adrenal Tumors | High-affinity binding to native, glycosylated INHA epitope (HEK293 expressed). |
| Therapeutic Biologics | Keros Therapeutics, Regeneron | Cancer Cachexia, Muscle Wasting, Anemia | Selectivity assays to prevent off-target cross-reactivity with Activin/TGF-beta family members. |
| Small Molecules / Antagonists | Academic/Biotech Consortiums | Reproductive Disorders, Endocrine Cancers | Stable cell lines overexpressing INHA for high-throughput screening (Lentivirus-driven). |